BidaskClub upgraded shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) from a strong sell rating to a sell rating in a report issued on Wednesday morning.

ADMS has been the subject of a number of other reports. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, August 11th. Noble Financial reiterated a buy rating on shares of Adamas Pharmaceuticals in a research report on Friday, May 12th. Mizuho reiterated a buy rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 6th. Finally, Cowen and Company set a $45.00 target price on shares of Adamas Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals currently has a consensus rating of Hold and an average target price of $32.50.

Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 19.93 on Wednesday. The stock’s 50 day moving average is $16.54 and its 200-day moving average is $16.78. The stock’s market capitalization is $448.70 million. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $21.44.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.81) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business’s revenue was down 90.9% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.78) earnings per share. Equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.80) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/27/bidaskclub-upgrades-adamas-pharmaceuticals-inc-adms-to-sell.html.

In other news, major shareholder Great Point Partners Llc sold 380,000 shares of the stock in a transaction dated Wednesday, June 21st. The shares were sold at an average price of $17.08, for a total value of $6,490,400.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 731,041 shares of company stock valued at $12,476,149 over the last quarter. Company insiders own 29.00% of the company’s stock.

Several large investors have recently modified their holdings of ADMS. State Street Corp boosted its stake in shares of Adamas Pharmaceuticals by 6.3% in the fourth quarter. State Street Corp now owns 257,685 shares of the specialty pharmaceutical company’s stock worth $4,356,000 after buying an additional 15,216 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Adamas Pharmaceuticals by 29.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 126,494 shares of the specialty pharmaceutical company’s stock worth $2,138,000 after buying an additional 28,994 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Adamas Pharmaceuticals by 28.4% in the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 3,358 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Adamas Pharmaceuticals by 2.4% in the first quarter. Bank of New York Mellon Corp now owns 65,830 shares of the specialty pharmaceutical company’s stock worth $1,152,000 after buying an additional 1,563 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Adamas Pharmaceuticals by 153.3% in the first quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock worth $1,956,000 after buying an additional 67,654 shares during the period. Institutional investors and hedge funds own 70.86% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.